Craig Horbinski

Summary

Affiliation: University of Kentucky
Country: USA

Publications

  1. doi Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas
    Craig Horbinski
    Department of Pathology, University of Kentucky, 800 Rose St, Lexington, KY 40536, USA
    Acta Neuropathol 119:641-9. 2010
  2. ncbi Practical molecular diagnostics in neuropathology: making a tough job a little easier
    Craig Horbinski
    Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky 40536, USA
    Semin Diagn Pathol 27:105-13. 2010
  3. pmc What do we know about IDH1/2 mutations so far, and how do we use it?
    Craig Horbinski
    Department of Pathology, University of Kentucky, 307 Combs Cancer Research Facility, 800 Rose Street, Lexington, KY 40536, USA
    Acta Neuropathol 125:621-36. 2013
  4. pmc To BRAF or not to BRAF: is that even a question anymore?
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, Kentucky 40536, USA
    J Neuropathol Exp Neurol 72:2-7. 2013
  5. pmc Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas
    Craig Horbinski
    Department of Pathology, University of Kentucky, MS 155, 800 Rose Street, Lexington, KY 40536, USA
    Neuro Oncol 14:777-89. 2012
  6. pmc The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, Kentucky, USA
    J Neuropathol Exp Neurol 71:73-82. 2012
  7. doi Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, KY 40536, USA
    Brain Pathol 21:57-73. 2011
  8. pmc Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, KY 40536, USA
    Brain Pathol 21:564-74. 2011
  9. pmc EGFR expression stratifies oligodendroglioma behavior
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, KY 40536, USA
    Am J Pathol 179:1638-44. 2011
  10. doi Low-grade recurrence of a congenital high-grade supratentorial tumor with astrocytic features in the absence of adjuvant therapy
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, Kentucky 40536, USA
    Neuropathology 31:286-91. 2011

Detail Information

Publications25

  1. doi Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas
    Craig Horbinski
    Department of Pathology, University of Kentucky, 800 Rose St, Lexington, KY 40536, USA
    Acta Neuropathol 119:641-9. 2010
    ..Nevertheless, such tumors may have altered sensitivity to pathway-specific adjuvant therapy. Additionally, deletion on 17p13 may be an adverse prognostic biomarker in cerebellar tumors...
  2. ncbi Practical molecular diagnostics in neuropathology: making a tough job a little easier
    Craig Horbinski
    Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky 40536, USA
    Semin Diagn Pathol 27:105-13. 2010
    ..Using specific cases as examples, this review illustrates how molecular testing is of great help in avoiding misdiagnoses and enhancing the quality of information provided to clinicians...
  3. pmc What do we know about IDH1/2 mutations so far, and how do we use it?
    Craig Horbinski
    Department of Pathology, University of Kentucky, 307 Combs Cancer Research Facility, 800 Rose Street, Lexington, KY 40536, USA
    Acta Neuropathol 125:621-36. 2013
    ....
  4. pmc To BRAF or not to BRAF: is that even a question anymore?
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, Kentucky 40536, USA
    J Neuropathol Exp Neurol 72:2-7. 2013
    ..Herein, these topics and different methods of testing for BRAF fusions and V600E point mutations are reviewed...
  5. pmc Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas
    Craig Horbinski
    Department of Pathology, University of Kentucky, MS 155, 800 Rose Street, Lexington, KY 40536, USA
    Neuro Oncol 14:777-89. 2012
    ....
  6. pmc The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, Kentucky, USA
    J Neuropathol Exp Neurol 71:73-82. 2012
    ..Thus, although PCR-based LOH is a better stratifier of 1p/19q status, FISH still has clinical and prognostic utility, especially if 10q data can be incorporated...
  7. doi Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, KY 40536, USA
    Brain Pathol 21:57-73. 2011
    ..Also discussed are lessons learned over the past decade, including common technical issues to consider when implementing and interpreting FISH results in a clinical setting...
  8. pmc Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, KY 40536, USA
    Brain Pathol 21:564-74. 2011
    ..5 vs. 46.1 years, P=0.0033). IDH1/2 testing of tumors suspected of being gangliogliomas may therefore be advisable, particularly in the adult population...
  9. pmc EGFR expression stratifies oligodendroglioma behavior
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, KY 40536, USA
    Am J Pathol 179:1638-44. 2011
    ....
  10. doi Low-grade recurrence of a congenital high-grade supratentorial tumor with astrocytic features in the absence of adjuvant therapy
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, Kentucky 40536, USA
    Neuropathology 31:286-91. 2011
    ..To the authors' knowledge, this is the first documented case of an untreated high-grade pediatric tumor that spontaneously differentiated into a low grade tumor. The clinical and biological implications of this are briefly discussed...
  11. pmc Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas
    Jonathan Hobbs
    Department of Pathology, University of Kentucky, Lexington, KY 40536, USA
    Am J Surg Pathol 36:1186-93. 2012
    ..91, respectively). These results suggest that GBMs with EGFR amplification are a heterogenous group of tumors and that behavior might differ according to the degree of amplification, although not in a straightforward dose-response manner...
  12. doi Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues
    Craig Horbinski
    Department of Pathology, University of Kentucky, Kentucky, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Neuropathol Exp Neurol 68:1319-25. 2009
    ..These results indicate that testing for IDH1/2 mutations can be effectively performed in a clinical setting and can enhance the accuracy of diagnosis of gliomas when traditional diagnostic methods are not definitive...
  13. doi The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas
    Craig Horbinski
    Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Arch Pathol Lab Med 134:1170-6. 2010
    ..Skull base chordomas are rare, locally aggressive, notochord-derived neoplasms for which prognostically relevant biomarkers are not well established...
  14. doi Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, KY, USA
    Brain Pathol 20:581-8. 2010
    ..These results suggest that PAs differ fundamentally according to location; therefore, biological behavior may not simply depend on extent of resection...
  15. pmc YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas
    Craig Horbinski
    Department of Pathology, Division of Neuropathology, University of Kentucky, 800 Rose Street, Lexington, KY 40536, USA
    Int J Clin Exp Pathol 3:226-37. 2010
    ..3), but loss of heterozygosity in 10q23 correlated with increased YKL-40 expression (P = 0.03). These data suggest that YKL-40 is predominantly expressed by neoplastic glial cells and is related to certain key molecular alterations...
  16. doi Comparison of telepathology systems in neuropathological intraoperative consultations
    Craig Horbinski
    Department of Pathology, Division of Neuropathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania15213, USA
    Neuropathology 29:655-63. 2009
    ..These results show that telepathology can be used to diagnose challenging tumors, and that differences in outcomes are as much a function of the different surgeries performed at different sites as is the diagnostic modality used...
  17. pmc Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies
    Craig Horbinski
    Department of Pathology, University of Kentucky, Lexington, Kentucky, USA
    J Mol Diagn 12:487-92. 2010
    ....
  18. doi Chordoid glioma: a case report and molecular characterization of five cases
    Craig Horbinski
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Brain Pathol 19:439-48. 2009
    ..These are the fifth through ninth reported cases of chordoid gliomas with molecular characterization suggesting a distinct genetic origin from other gliomas...
  19. doi Primary intracranial dural-based synovial sarcoma with an unusual SYT fluorescence in situ hybridization pattern
    Craig Horbinski
    Department of Pathology, University of Pittsburgh, Pennsylvania, USA
    J Neurosurg 109:897-903. 2008
    ....
  20. pmc PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma
    Joanna J Phillips
    Department of Pathology, University of California San Francisco, San Francisco, CA, USA
    Brain Pathol 23:565-73. 2013
    ..To our knowledge, this is the largest survey of PDGFRA status in adult and pediatric HGAs and suggests PDGFRA amplification increases with grade and is associated with a less favorable prognosis in IDH1 mutant de novo GBMs. ..
  21. doi How molecular testing can help (and hurt) in the workup of gliomas
    Kenneth Clark
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Am J Clin Pathol 139:275-88. 2013
    ..To avoid errors, however, the significance and controversies associated with each test must be thoroughly understood...
  22. pmc Molecular and clinical characterization of a recurrent cryptic unbalanced t(4q;18q) resulting in an 18q deletion and 4q duplication
    Craig Horbinski
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Am J Med Genet A 146:2898-904. 2008
    ..Individuals with features suggestive of this 4q;18q translocation but a normal karyotype warrant aCGH or subtelomere studies...
  23. doi Autophagy and oxidative stress in gliomas with IDH1 mutations
    Misty R Gilbert
    Department of Pathology and Laboratory Medicine, University of Kentucky, 307 Combs Building, Lexington, KY, 40536, USA
    Acta Neuropathol 127:221-33. 2014
    ..These data indicate that mutant IDH1 and 2-HG can induce oxidative stress, autophagy, and apoptosis, but these effects vary greatly according to cell type. ..
  24. doi Application of telepathology for neuropathologic intraoperative consultations
    Craig Horbinski
    Department of Pathology, Division of Neuropathology, University of Pittsburgh Medical Center, 3615 Civic Center Boulevard, Philadelphia, PA 19104 4318, USA
    Brain Pathol 19:317-22. 2009
    ..Given the improvements in technology and the multiple uses of telepathology, this method for delivering patient care will undoubtedly continue to grow over time...
  25. doi The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management
    Joan M Striebel
    Department of Pathology, Magee Womens Hospital, Pittsburgh, PA 15213, USA
    Am J Clin Pathol 129:383-90. 2008
    ..These results support the recent American Society of Clinical Oncology/College of American Pathologists recommendations for further testing in cases with equivocal HER2 results...